KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 69,184 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were bought at an average price of $12.44 per share, with a total value of $860,648.96. Following the completion of the purchase, the […]
Insider Selling: KalVista Pharmaceuticals, Inc (NASDAQ:KALV) Insider Sells 22,679 Shares of Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald Reiterates Overweight Rating for KalVista Pharmaceuticals (NASDAQ:KALV) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) is set to release its earnings data on Wednesday, July 5th. KalVista Pharmaceuticals Price Performance Shares of NASDAQ:KALV opened at $9.04 on Tuesday. The firm has a market capitalization of $308.90 million, a PE ratio of -2.53 and a beta of 1.06. The business has a 50-day moving average […]